Is Predictive Oncology Stock a Good Investment?
Predictive Oncology Investment Advice | POAI |
- Examine Predictive Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Predictive Oncology's leadership team and their track record. Good management can help Predictive Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Predictive Oncology's business and its evolving consumer preferences.
- Compare Predictive Oncology's performance and market position to its competitors. Analyze how Predictive Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Predictive Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Predictive Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Predictive Oncology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Predictive Oncology is a good investment.
Sell | Buy |
Hold
Market Performance | OK | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Predictive Oncology Stock
Researching Predictive Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was at this time reported as 0.3. The company recorded a loss per share of 2.96. Predictive Oncology last dividend was issued on the 29th of October 2019. The entity had 1:20 split on the 24th of April 2023.
To determine if Predictive Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Predictive Oncology's research are outlined below:
| Predictive Oncology is way too risky over 90 days horizon | |
| Predictive Oncology may become a speculative penny stock | |
| Predictive Oncology appears to be risky and price may revert if volatility continues | |
| Predictive Oncology has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.78 M. Net Loss for the year was (13.98 M) with profit before overhead, payroll, taxes, and interest of 681.38 K. | |
| Predictive Oncology currently holds about 25.39 M in cash with (13.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Predictive Oncology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by St. Clair Gregory Sr of 6265 shares of Predictive Oncology subject to Rule 16b-3 |
Predictive Oncology Quarterly Liabilities And Stockholders Equity |
|
Predictive Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Predictive Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Predictive Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Predictive Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Predictive Oncology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-12 | 2022-03-31 | -0.04 | -0.05 | -0.01 | 25 | ||
2021-08-11 | 2021-06-30 | -0.07 | -0.05 | 0.02 | 28 | ||
2021-05-12 | 2021-03-31 | -0.09 | -0.11 | -0.02 | 22 | ||
2021-11-10 | 2021-09-30 | -0.05 | -0.08 | -0.03 | 60 | ||
2023-03-21 | 2022-12-31 | -0.06 | -0.1 | -0.04 | 66 | ||
2022-11-10 | 2022-09-30 | -0.01 | -0.05 | -0.04 | 400 | ||
2022-03-31 | 2021-12-31 | -0.02 | -0.13 | -0.11 | 550 | ||
2022-08-11 | 2022-06-30 | -0.03 | -0.15 | -0.12 | 400 |
Know Predictive Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Predictive Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Predictive Oncology backward and forwards among themselves. Predictive Oncology's institutional investor refers to the entity that pools money to purchase Predictive Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Psi Advisors, Llc | 2024-12-31 | 399 | Bank Of America Corp | 2024-12-31 | 51.0 | Royal Bank Of Canada | 2024-12-31 | 50.0 | Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 50.0 | Sbi Securities Co Ltd | 2024-12-31 | 14.0 | Susquehanna International Group, Llp | 2024-12-31 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-12-31 | 0.0 | Vanguard Group Inc | 2024-12-31 | 71.3 K | Geode Capital Management, Llc | 2024-12-31 | 51.2 K |
Predictive Oncology's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8 M.Market Cap |
|
Predictive Oncology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.89) | (0.93) | |
| Return On Capital Employed | (1.55) | (1.62) | |
| Return On Assets | (0.87) | (0.92) | |
| Return On Equity | (1.94) | (2.04) |
Determining Predictive Oncology's profitability involves analyzing its financial statements and using various financial metrics to determine if Predictive Oncology is a good buy. For example, gross profit margin measures Predictive Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Predictive Oncology's profitability and make more informed investment decisions.
Evaluate Predictive Oncology's management efficiency
Predictive Oncology has return on total asset (ROA) of (0.6644) % which means that it has lost $0.6644 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0146) %, meaning that it created substantial loss on money invested by shareholders. Predictive Oncology's management efficiency ratios could be used to measure how well Predictive Oncology manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.93. The current Return On Capital Employed is estimated to decrease to -1.62. As of now, Predictive Oncology's Net Tangible Assets are increasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.85 | 1.95 | |
| Tangible Book Value Per Share | 1.80 | 1.89 | |
| Enterprise Value Over EBITDA | (0.50) | (0.53) | |
| Price Book Value Ratio | 1.44 | 1.37 | |
| Enterprise Value Multiple | (0.50) | (0.53) | |
| Price Fair Value | 1.44 | 1.37 | |
| Enterprise Value | 8.4 M | 12.6 M |
Evaluating the management effectiveness of Predictive Oncology allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Predictive Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 1.223 |
Basic technical analysis of Predictive Stock
As of the 24th of March, Predictive Oncology holds the Risk Adjusted Performance of 0.0948, coefficient of variation of 1035.75, and Semi Deviation of 6.76. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Predictive Oncology, as well as the relationship between them.Predictive Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Predictive Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Predictive Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Predictive Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Predictive Oncology's Outstanding Corporate Bonds
Predictive Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Predictive Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Predictive bonds can be classified according to their maturity, which is the date when Predictive Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Predictive Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Predictive Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0948 | |||
| Market Risk Adjusted Performance | 1.22 | |||
| Mean Deviation | 6.96 | |||
| Semi Deviation | 6.76 | |||
| Downside Deviation | 7.53 | |||
| Coefficient Of Variation | 1035.75 | |||
| Standard Deviation | 11.05 | |||
| Variance | 122.17 | |||
| Information Ratio | 0.1017 | |||
| Jensen Alpha | 1.12 | |||
| Total Risk Alpha | 1.9 | |||
| Sortino Ratio | 0.1494 | |||
| Treynor Ratio | 1.21 | |||
| Maximum Drawdown | 80.58 | |||
| Value At Risk | (9.70) | |||
| Potential Upside | 16.54 | |||
| Downside Variance | 56.67 | |||
| Semi Variance | 45.69 | |||
| Expected Short fall | (9.55) | |||
| Skewness | 2.25 | |||
| Kurtosis | 10.27 |
| Risk Adjusted Performance | 0.0948 | |||
| Market Risk Adjusted Performance | 1.22 | |||
| Mean Deviation | 6.96 | |||
| Semi Deviation | 6.76 | |||
| Downside Deviation | 7.53 | |||
| Coefficient Of Variation | 1035.75 | |||
| Standard Deviation | 11.05 | |||
| Variance | 122.17 | |||
| Information Ratio | 0.1017 | |||
| Jensen Alpha | 1.12 | |||
| Total Risk Alpha | 1.9 | |||
| Sortino Ratio | 0.1494 | |||
| Treynor Ratio | 1.21 | |||
| Maximum Drawdown | 80.58 | |||
| Value At Risk | (9.70) | |||
| Potential Upside | 16.54 | |||
| Downside Variance | 56.67 | |||
| Semi Variance | 45.69 | |||
| Expected Short fall | (9.55) | |||
| Skewness | 2.25 | |||
| Kurtosis | 10.27 |
Consider Predictive Oncology's intraday indicators
Predictive Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Predictive Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Predictive Oncology time-series forecasting models is one of many Predictive Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Predictive Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Predictive Stock media impact
Far too much social signal, news, headlines, and media speculation about Predictive Oncology that are available to investors today. That information is available publicly through Predictive media outlets and privately through word of mouth or via Predictive internal channels. However, regardless of the origin, that massive amount of Predictive data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Predictive Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Predictive Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Predictive Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Predictive Oncology alpha.
Predictive Oncology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Predictive Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Predictive Oncology Corporate Management
| Joshua MBA | Interim Officer | Profile | |
| BS BSc | VP RD | Profile | |
| Pamela MBA | Chief Officer | Profile | |
| Raymond Vennare | CEO Chairman | Profile | |
| DSc OD | VP Operations | Profile | |
| Julia Kirshner | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth (0.49) | Return On Assets | Return On Equity |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Predictive Oncology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.